593 related articles for article (PubMed ID: 31870950)
1. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
3. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
4. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
[TBL] [Abstract][Full Text] [Related]
5. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
[TBL] [Abstract][Full Text] [Related]
6. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
[TBL] [Abstract][Full Text] [Related]
9. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282
[TBL] [Abstract][Full Text] [Related]
12. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease.
Bassegoda O; Olivas P; Turco L; Mandorfer M; Serra-Burriel M; Tellez L; Kwanten W; Laroyenne A; Farcau O; Alvarado E; Moga L; Vuille-Lessard E; Fortea JI; Ibañez L; Tosetti G; Vanwolleghem T; Larrue H; Burgos-Santamaría D; Stefanescu H; Paternostro R; Cippitelli A; Lens S; Augustin S; Llop E; Laleman W; Trebicka J; Chang J; Masnou H; Zipprich A; Miceli F; Semmler G; Forns X; Primignani M; Bañares R; Puente A; Berzigotti A; Rautou PE; Villanueva C; Ginès P; Garcia-Pagan JC; Procopet B; Bureau C; Albillos A; Francque S; Reiberger T; Schepis F; Graupera I; Hernandez-Gea V
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2276-2286.e6. PubMed ID: 34688952
[TBL] [Abstract][Full Text] [Related]
13. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
15. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
[TBL] [Abstract][Full Text] [Related]
16. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
17. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
[TBL] [Abstract][Full Text] [Related]
19. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Vukotic R; Di Donato R; Roncarati G; Simoni P; Renzulli M; Gitto S; Schepis F; Villa E; Berzigotti A; Bosch J; Andreone P
J Hepatol; 2023 Oct; 79(4):977-988. PubMed ID: 37482222
[TBL] [Abstract][Full Text] [Related]
20. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]